Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 4/20 | 0.52 |
| ▸ | F10 | P00742 | 4/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.48 |
| ▸ | PARP1 | P09874 | 2/20 | 0.47 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.47 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30417904 | 0.96 | F10 (0.55) | F10MAPK10HDAC8HDAC6MAPK8 | |
| SCHEMBL12822364 | 0.96 | F10 (0.55) | F10MAPK10HDAC8HDAC6MAPK8 | |
| SCHEMBL30417796 | 0.91 | FOLH1 (0.60) | FOLH1F10HDAC8HDAC6PARP1 | |
| SCHEMBL29568679 | 0.91 | FOLH1 (0.60) | FOLH1F10HDAC8HDAC6PARP1 | |
| SCHEMBL12822199 | 0.91 | FOLH1 (0.60) | FOLH1F10HDAC8HDAC6PARP1 | |
| SCHEMBL20421481 | 0.82 | HDAC8 (0.53) | F10MAPK10HDAC8HDAC6PARP1 | |
| SCHEMBL23997296 | 0.82 | LMNA (0.53) | F10MAPK10MAPK8 | |
| SCHEMBL30345095 | 0.82 | LMNA (0.53) | F10MAPK10MAPK8 | |
| SCHEMBL12822214 | 0.81 | PARP1 (0.47) | F10HDAC8HDAC6PARP1PARP2 | |
| SCHEMBL12822057 | 0.81 | FOLH1 (0.52) | FOLH1HDAC8HDAC6PARP1PLA2G10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2709990-A1 | 1-(ARYLMETHYL)QUINAZOLINE-2,4(1H,3H)-DIONES AS PARP INHIBITORS AND THE USE THEREOF | Impact Therapeutics, Inc. (CN) | 2014-03-26 | — | — | EP | disclosed |
| WO-2012130166-A1 | 1-(ARYLMETHYL)QUINAZOLINE-2,4(1H,3H)-DIONES AS PARP INHIBITORS AND THE USE THEREOF | IMPACT THERAPEUTICS, INC. (CN) | 2012-10-04 | — | — | WO | disclosed |